Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF gargle for prevention and treatment of radiation-induced oral mucositis in head and neck cancer
ChiCTR2400084395Phase 3Not yet recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegfilgrastim in stomatitis (2 arms), sponsored by Foshan First People's Hospital. Primary endpoint: Incidence of acute radiation-induced oral mucositis of grade III or higher. Planned start May 2024; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
stomatitis
Beyond the preview
Go deeper on ChiCTR2400084395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084395.